Clinical Trial Detail

NCT ID NCT04123379
Title Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications

hepatocellular carcinoma

lung non-small cell carcinoma

Therapies

BMS-813160 + Nivolumab

Nivolumab

BMS-986253 + Nivolumab

Age Groups: senior adult

No variant requirements are available.